


TRANSFORMATIVE THERAPIES | TARGETING CANCER

Seattle Genetics, Inc. is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people's lives.

ADCETRIS® (brentuximab vedotin) uses the company's industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company has established a pipeline of novel targeted therapies at various stages of clinical testing, including three in ongoing pivotal trials for solid tumors. Positive topline results from our pivotal trial of enfortumab vedotin (EV) for metastatic urothelial cancer were announced in March 2019. Both EV and tisotumab vedotin for metastatic cervical cancer use our proprietary ADC technology. Tucatinib, a small molecule tyrosine kinase inhibitor, is in a pivotal trial for HER2-positive metastatic breast cancer. We are leveraging our expertise in empowered antibodies and targeted therapies to build a portfolio of programs for hematologic malignancies and solid tumors. The company is headquartered in Bothell, Washington, and has a European office in Zug, Switzerland.

Our ADC technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer.



Various combinations of these novel modalities are likely to be the future of treatment in oncology

QUICK FACTS

YEARS: 20th anniversary in 2018

SIZE: Largest biotechnology company in the Pacific Northwest

EMPLOYEES: 1,300+ employees worldwide

PASSION: Helping people with cancer

LEADERS: In antibody-drug conjugate (ADC) technology

COMMERCIAL PRODUCT: ADCETRIS® (brentuximab vedotin) for multiple CD30-expressing lymphomas

RESEARCH & DEVELOPMENT:

>750 scientists dedicated to developing our next innovations, and medical and clinical researchers focused on improving patient outcomes with targeted treatment options, including three unique programs in ongoing pivotal clinical trials

COLLABORATIONS: Multiple ADC technology licensing agreements; co-development collaborations with other oncology industry leaders

LOCATIONS: Greater Seattle and South San Francisco, United States; Zug, Switzerland

For more information on our company and our robust pipeline, we encourage you to visit www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

PHASE 1 PHASE 2 PHASE 3

BRENTUXIMAB VEDOTIN

ADCETRIS® (brentuximab vedotin) is currently approved in the U.S. for six indications for certain CD30-expressing lymphomas. We continue to evaluate ADCETRIS in a broad clinical development program.

Hodgkin Lymphoma (HL)




Non-Hodgkin Lymphoma (NHL)




LATE-STAGE PROGRAMS

We believe our multiple promising late-stage programs have the potential to help us achieve our goal of bringing additional new treatment options to patients in need.



EARLY-STAGE PROGRAMS



¹ Program being developed in collaboration with Astellas
² Program being developed in collaboration with Genmab
³ Program being developed in collaboration with Unum

These are investigational uses/agents and efficacy/safety have not been established. There is no guarantee that these agents will receive regulatory approval and become commercially available for uses being investigated.